'Reverse vaccine' for diabetes passes test
LOS ANGELES — A “reverse vaccine” that allows people with Type 1 diabetes to produce their own insulin has passed its first test with human subjects, according to a new study. The success points to a potential strategy for treating those in the early stages of the disease, experts said.
The therapy is designed to protect cells in the pancreas that make insulin, a hormone the body needs to convert sugars and starches into energy. In people with Type 1 diabetes, the immune system goes haywire and attacks those crucial insulin-producing cells for reasons that medical researchers don't understand.
Researchers dubbed the treatment a reverse vaccine because it suppresses the immune system, instead of stimulating it. As hoped, the experimental vaccine reduced the number of immune system “killer” cells that went on the attack.
“We're trying to turn off one specific immune response,” said Dr. Lawrence Steinman, an immunologist at Stanford University and senior author of the study published Wednesday in Science Translational Medicine.
About 1.25 million Americans have Type 1 diabetes.
Show commenting policy
TribLive commenting policy
- Alamo named as World Heritage site by United Nations
- Police: Maine man shoots firework from top of his head, dies
- Risk of government shutdown to worry Congress on return from July Fourth
- Measles carries risk of deadly complication for young
- Notorious New York escapee Sweat returns to prison
- Deteriorating nails blamed for North Carolina deck collapse
- Austin police kill gunman in slaying in hotel lobby
- Years will be needed to gauge efforts to cut Lake Erie algae
- Republican Christie criticizes high court’s gay marriage ruling
- Woman who tries to sneak on planes arrested twice in 2 days
- Arizona prison to relocate more than 350 inmates after disturbance